Jason R. Brown

2.3k total citations · 1 hit paper
54 papers, 1.5k citations indexed

About

Jason R. Brown is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jason R. Brown has authored 54 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 26 papers in Surgery and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jason R. Brown's work include Bladder and Urothelial Cancer Treatments (22 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Urinary and Genital Oncology Studies (9 papers). Jason R. Brown is often cited by papers focused on Bladder and Urothelial Cancer Treatments (22 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Urinary and Genital Oncology Studies (9 papers). Jason R. Brown collaborates with scholars based in United States, United Kingdom and Spain. Jason R. Brown's co-authors include David L. Rimm, Kurt A. Schalper, Hallie Wimberly, Lajos Pusztai, Donald R. Lannin, Veerle Bossuyt, Christian P. Nixon, Daniel Carvajal, Vamsidhar Velcheti and Daniel Carvajal‐Hausdorf and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Jason R. Brown

42 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

2014 367 citations Kurt A. Schalper, Hallie Wimberly et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Jason R. Brown

Since Specialization

Citations

This map shows the geographic impact of Jason R. Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason R. Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason R. Brown more than expected).

Fields of papers citing papers by Jason R. Brown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason R. Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason R. Brown. The network helps show where Jason R. Brown may publish in the future.

Co-authorship network of co-authors of Jason R. Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Jason R. Brown. A scholar is included among the top collaborators of Jason R. Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason R. Brown. Jason R. Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure? 2025 ·The Oncologist ·Albert Jang, (unknown), (unknown), (unknown), Prateek Jain, Adam Calaway, Jonathan E. Shoag, Randy Vince, Prateek Mendiratta, Santosh Rao, Jorge A. García, Jason R. Brown, Vadim S. Koshkin, Matthew T. Campbell, (unknown), Pedro C. Barata	0
2	3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y 2025 ·Annals of Oncology ·Terence W. Friedlander, Peter H. O’Donnell, (unknown), Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig, Nataliya Mar, Helen Moon, Rana R. McKay, (unknown), Saby George, Jason R. Brown, Mehmet Asım Bilen, Delphine Borchiellini, Marco Iafolla, Abhishek Bavle, M. C. Mihm, Y. Zhu, Changting Meng, Jacob Rosenberg	0
3	Real-world analysis of 2IR immune response score in urothelial carcinoma (UC). 2025 ·Journal of Clinical Oncology ·Jason R. Brown, Tolulope Adeyelu, Andrew Elliott, Arnab Basu, Mehmet Asım Bilen, Roger Li, Tyler F. Stewart, Rana R. McKay, Elisabeth I. Heath, (unknown), (unknown), Pedro C. Barata	1
4	A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design. 2025 ·Journal of Clinical Oncology ·Sarmad Sadeghi, (unknown), Primo N. Lara, Stephanie Berg, Jason R. Brown, Rick Bangs, (unknown), Siamak Daneshmand, (unknown), Thomas W. Flaig, Daniel P. Petrylak, Seth P. Lerner	0
5	Androgen suppression with abiraterone acetate, leuprolide, PARP inhibition, and stereotactic body radiotherapy (ASCLEPIuS) in high-risk and node positive prostate cancer (PCa): Phase I multicenter results. 2025 ·Journal of Clinical Oncology ·Will Jackson, Robert T. Dess, Angela Y. Jia, Himanshu Nagar, Neil Desai, Raquibul Hannan, Jason W.D. Hearn, Zachery R. Reichert, Ariel E. Marciscano, Brian J. Davis, (unknown), Nicholas G. Zaorsky, Jorge A. García, Pedro C. Barata, Jason R. Brown, Prateek Mendiratta, Felix Y. Feng, Arul M. Chinnaiyan, Krithika Suresh, Daniel E. Spratt	0
6	Management of Neonatal Airway Obstruction: A Point‐Counterpoint Ethical Discussion 2024 ·Otolaryngology ·(unknown), (unknown), (unknown), Jason R. Brown	0
7	Identification and Validation of Prognostic Model for Tumor Microenvironment-Associated Genes in Bladder Cancer Based on Single-Cell RNA Sequencing Data Sets 2024 ·JCO Precision Oncology ·(unknown), Henkel Valentine, (unknown), John P. Sfakianos, Robert G. Uzzo, Shilpa Gupta, Jason R. Brown, Daniel Ranti, Elizabeth R. Plimack, George Haber, Christopher Weight, Alexander Kutikov, Philip H. Abbosh, Laura Bukavina	2
8	Impact of Tracheostomy Status on Sternal Wound Infections in Children Following Median Sternotomy 2024 ·Otolaryngology ·(unknown), (unknown), Janelle Noel‐MacDonnell, (unknown), Jason R. Brown, James E. O’Brien, Daniel R. Jensen	0
9	Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study. 2024 ·Journal of Clinical Oncology ·(unknown), Omar Alhalabi, (unknown), Dimitra Rafailia Bakaloudi, Amanda Nizam, Mehmet Asım Bilen, Arnab Basu, Yousef Zakharia, Matthew I. Milowsky, Jason R. Brown, Deepak Kilari, Sumit Shah, Hamid Emamekhoo, Petros Grivas, Christopher Hoimes, Shilpa Gupta, Joaquim Bellmunt, Matthew T. Campbell, Ajjai Alva, Vadim S. Koshkin	1
10	Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation 2024 ·Cancer Research Communications ·Laura Bukavina, Rashida Ginwala, (unknown), (unknown), Megan Prunty, Daniel M. Geynisman, Pooja Ghatalia, Henkel Valentine, Adam Calaway, Andres Correa, Jason R. Brown, Kirtishri Mishra, Elizabeth R. Plimack, Alexander Kutikov, Mahmoud A. Ghannoum, Mohammed Elshaer, (unknown), Lee Ponsky, Robert G. Uzzo, Philip H. Abbosh	6
11	Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study 2024 ·Clinical Genitourinary Cancer ·Petros Grivas, Pedro Barata, Helen Moon, Shilpa Gupta, (unknown), Cora N. Sternberg, Jason R. Brown, (unknown), (unknown), Alicia C. Shillington, Howard M. Katzenstein, (unknown), (unknown), (unknown), Valerie Morris, (unknown), Guru Sonpavde	5
12	Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC). 2023 ·Journal of Clinical Oncology ·(unknown), Dimitra Rafailia Bakaloudi, (unknown), (unknown), (unknown), Dimitrios Makrakis, Nishita Tripathi, Neeraj Agarwal, (unknown), Vadim S. Koshkin, Jason R. Brown, Jeffrey S. Johnson, Yousef Zakharia, Joseph J. Park, Ajjai Alva, Rafael Morales‐Barrera, Alexandra Drakaki, Pedro C. Barata, Ali Raza Khaki, Petros Grivas	0
13	Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review 2023 ·Expert Review of Anticancer Therapy ·(unknown), (unknown), Jorge A. García, Prateek Mendiratta, Pedro C. Barata, Angela Y. Jia, Daniel E. Spratt, Jason R. Brown	28
14	Cervical Necrotizing Fasciitis and Shock in the Post-Operative Pediatric Patient 2022 ·Ear Nose & Throat Journal ·(unknown), Jason R. Brown	0
15	Internal carotid artery position to characterize risk for vessel injury in pediatric intraoral trauma 2022 ·International Journal of Pediatric Otorhinolaryngology ·(unknown), Emily Cramer, (unknown), (unknown), Jason R. Brown	1
16	Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance 2017 ·Breast Cancer Research ·Vasiliki Pelekanou, Daniel Carvajal‐Hausdorf, Mehmet Altan, Brad Wasserman, (unknown), Hallie Wimberly, Jason R. Brown, Donald R. Lannin, Lajos Pusztai, David L. Rimm	86
17	Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer 2014 ·Clinical Cancer Research ·Jason R. Brown, Hallie Wimberly, Donald R. Lannin, Christian P. Nixon, David L. Rimm, Veerle Bossuyt	129
18	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer 2014 ·Cancer Immunology Research ·Hallie Wimberly, Jason R. Brown, Kurt A. Schalper, Herbert Haack, Matthew R. Silver, Christian P. Nixon, Veerle Bossuyt, Lajos Pusztai, Donald R. Lannin, David L. Rimm	312
19	Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancer 2014 ·Histochemistry and Cell Biology ·Joan How, Jason R. Brown, (unknown), David L. Rimm	8
20	Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer 2013 ·Laboratory Investigation ·Jason R. Brown, Michael P. DiGiovanna, Brigid K. Killelea, Donald R. Lannin, David L. Rimm	83

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact